93 Results for "

CSF-1R Inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (93)

93 Results for "CSF-1R Inhibitor" in MCE Product Catalog:

Cat. No.: HY-101526
CAS No.: 2070864-35-4
Synonyms: RA03546849
Target:  

c-Fms

Research Areas:  

Inflammation/Immunology

GENZ-882706 is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1.
loading...
    loading...
Cat. No.: HY-153012
CAS No.: 2394874-60-1
Target:  

TAM Receptor c-Fms

Research Areas:  

Cancer

Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with Kds of <0.1 μM .
loading...
    loading...
Cat. No.: HY-159503A
CAS No.: 2847066-15-1
Synonyms: 3D185; HH185
Target:  

FGFR c-Fms

Research Areas:  

Cancer

Segigratinib hydrochloride (3D185) is a potent inhibitor of FGFR1/2/3 and CSF-1R; The IC50 values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity .
loading...
    loading...
Cat. No.: HY-50905R
CAS No.: 405169-16-6
Synonyms: CHIR-258 (Standard); TKI258 (Standard)
Research Areas:  

Cancer

Dovitinib (Standard) is the analytical standard of Dovitinib. This product is intended for research and analytical applications. Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity .
loading...
    loading...
Cat. No.: HY-101034
CAS No.: 2081093-21-0
Synonyms: CHMFL-ABL-KIT-155
Research Areas:  

Cancer

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC50=81 nM), CSF1R (IC50=227 nM), DDR1 (IC50=116 nM), DDR2 (IC50=325 nM), LCK (IC50=12 nM) and PDGFRβ (IC50=80 nM) kinases. CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155) arrests cell cycle progression and induces apoptosis .
loading...
    loading...
Cat. No.: HY-147609
CAS No.: 2765301-60-6
Target:  

c-Fms

Research Areas:  

Cancer

CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor with an IC50 of 0.012 μM .
loading...
    loading...
Cat. No.: HY-147611
CAS No.: 2765301-88-8
Target:  

c-Fms

Research Areas:  

Cancer

CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor with an IC50 of 0.005 μM .
loading...
    loading...
Cat. No.: HY-144041
CAS No.: 2716184-93-7
Target:  

c-Fms

Research Areas:  

Cancer

CSF1R-IN-5 is a potent inhibitor of CSF1R. CSF-1R is expressed in macrophages, and the survival and differentiation of macrophages depends on the CSF-1/CSF-1R signaling pathway. CSF1R-IN-5 affects the exchange of inflammatory factors between TAMs and glioma cells. CSF1R-IN-5 has the potential for the research of cancer disease (extracted from patent WO2021197276A1, compound 11) .
loading...
    loading...
Cat. No.: HY-162309
CAS No.: 2935479-57-3
Target:  

c-Fms

Research Areas:  

Cancer

CSF1R-IN-20 (compound 7a) is a CSF-1R Inhibitor with an IC50 value of 467 nM. CSF1R-IN-20 inhibits CSF-1R auto-phosphorylation .
loading...
    loading...
Cat. No.: HY-168954
Target:  

c-Fms Apoptosis Akt ERK STAT

Research Areas:  

Inflammation/Immunology Cancer

CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .
loading...
    loading...
Cat. No.: HY-155001
CAS No.: 2925744-43-8
Target:  

c-Fms

Research Areas:  

Others

CSF1R-IN-15 (compound 23) is an inhibitor targeting CSF1R. The colony-stimulating factor-1 receptor (CSF1R) is a tyrosine kinase embedded in the cell membrane of macrophages. The receptor is activated by colony-stimulating factor-1 (CSF-1) and interleukin-34, and signaling via CSF1R is crucial for the differentiation, proliferation, and survival of macrophages .
loading...
    loading...
Cat. No.: HY-153243
CAS No.: 2231259-36-0
Target:  

c-Fms

Research Areas:  

Cancer

IACS-9439 is a potent, selective, and orally active CSF1R inhibitor with a Ki value of 1 nM inhibitor. IACS-9439 can be used for advanced solid tumors research .
loading...
    loading...
Cat. No.: HY-13075
CAS No.: 885704-21-2
Purity:  99.69%
c-Fms-IN-3 is an orally active c-Fms (CSF1R) kinase inhibitor (IC50 = 0. 8 nM). c-Fms-IN-3 inhibits CSF1R kinase activity and reduces macrophage populations. c-Fms-IN-3 reduces bone erosion, pannus invasion, cartilage damage, and inflammation in collagen (HY-NP003)-induced arthritis mouse model. c-Fms-IN-3 is useful for arthritis research .
loading...
    loading...
Cat. No.: HY-153920A
CAS No.: 2866305-19-1
Synonyms: ABSK021 hydrochloride
Target:  

c-Fms c-Kit PDGFR

Research Areas:  

Cancer

Pimicotinib (ABSK021) hydrochloride is a selective and orally active CSF1R inhibitor with an IC50 value of 19.48 nM (determined by inhibiting ADP production). Pimicotinib hydrochloride exhibits anti-tumor activity .
loading...
    loading...
Cat. No.: HY-13493A
CAS No.: 1351522-05-8
Target:  

PDGFR

Research Areas:  

Cancer

AC710 Mesylate is a potent PDGFR inhibitor with Kds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.
loading...
    loading...
Cat. No.: HY-16749AR
CAS No.: 2040295-03-0
Synonyms: PLX-3397 hydrochloride (Standard)
Research Areas:  

Cancer

Pexidartinib (hydrochloride) (Standard) is the analytical standard of Pexidartinib (hydrochloride). This product is intended for research and analytical applications. Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive colony stimulating factor 1 receptor (CSF1R or M-CSFR) and c-Kit inhibitor, with IC50s of 20 and 10 nM, respectively. Pexidartinib hydrochloride exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases. Pexidartinib hydrochloride induces cell apoptosis and has anti-cancer activity .
loading...
    loading...
Cat. No.: HY-12768B
CAS No.: 2222138-40-9
Synonyms: BLZ945 dihydrochloride
Target:  

c-Fms

Research Areas:  

Neurological Disease Cancer

Sotuletinib (BLZ945) dihydrochloride is a potent, selective, orally active and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. Sotuletinib dihydrochloride can be used for microglia depletion, and for tumor and CNS-related disease research .
loading...
    loading...
Cat. No.: HY-13496
CAS No.: 885692-52-4
Target:  

c-Fms

Research Areas:  

Inflammation/Immunology Cancer

JNJ-28312141 is an inhibitor for colony-stimulating factor-1 receptor (CSF-1R or FMS), with an IC50 of 0.69 nM. JNJ-28312141 inhibits proliferation of BDBM, MV-4-11, M-o7e, TF-1 with an IC50s of 2.6, 21, 41 and 150 nM, respectively. JNJ-28312141 exhibits anti-inflammatory activity in mouse arthritis model .
loading...
    loading...
Cat. No.: HY-176194
Target:  

Collagen c-Fms PDGFR Src

Research Areas:  

Inflammation/Immunology

Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model .
loading...
    loading...
Cat. No.: HY-152830A
Purity:  99.82%
Synonyms: Q702 TFA
Target:  

c-Fms TAM Receptor MHC

Research Areas:  

Cancer

Adrixetinib (Q702) TFA is an orally active triple inhibitor against CSF1R, Mer, and Axl, with Kd values of 8.7 nM, 0.8 nM, and 0.3 nM, respectively. Adrixetinib TFA acts as a potent immune modulator that remodels the tumor microenvironment. Adrixetinib TFA increases the abundance of M1 macrophages and CD8⁺ T cells, while decreasing the levels of M2 macrophages and myeloid-derived suppressor cells (MDSCs). Adrixetinib TFA upregulates the expression of MHC class I and E-cadherin in tumor cells. Adrixetinib TFA shows remarkable antitumor efficacy in syngeneic mouse tumor models. Adrixetinib TFA is suitable for the research of breast cancer, renal adenocarcinoma, colon carcinoma, and melanoma .
loading...
    loading...